Direct Factor Xa Inhibitor (DOAC)

Edoxaban (AF Stroke Prevention / VTE)

Brand names: Lixiana, Savaysa (US)

Edoxaban is a direct oral anticoagulant (a factor Xa inhibitor) used for stroke prevention in atrial fibrillation and for the treatment and prevention of venous thromboembolism.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

US labelling (FDA)

Reference — US labelling, may differ from UK

Treatment of NVAF: Assess CrCL before initiating therapy ( 2.1 ) The recommended dose is 60 mg once daily in patients with CrCL >50 to ≤ 95 mL/min. Do not use SAVAYSA in patients with CrCL > 95 mL/min ( 2.1 ) Reduce dose to 30 mg once daily in patients with creatinine clearance 15 to 50 mL/min ( 2.1 ) Treatment of DVT and PE: The recommended dose is 60 mg once daily ( 2.2 ) Reduce dose to 30 mg once daily for patients with CrCL 15 to 50 mL/min or body weight less than or equal to 60 kg or who use certain P-gp inhibitors ( 2.2 ) 2.1 Nonvalvular Atrial Fibrillation The recommended dose of SAVAYSA is 60 mg taken orally once daily [see Warnings and Precautions (5.1) and Clinical Studies (14.1) …

Source: US FDA prescribing information (openFDA / DailyMed), label dated 2025-07-10. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.

Clinical monograph

How it works

It directly and reversibly inhibits activated factor Xa, reducing thrombin generation and clot formation.

Prescribing in practice

Bleeding is the main risk; assess bleeding and thrombotic risk, and the dose depends on renal function and body weight.
In atrial fibrillation, efficacy may be reduced in patients with high creatinine clearance, which is a labelled caution when choosing therapy.
It is taken once daily and does not require routine anticoagulant monitoring.

Monitoring

Monitor renal function, full blood count and for signs of bleeding; reassess if renal function or weight changes.

Counselling the patient

Report unusual bruising or bleeding, black stools or blood in the urine.
Do not stop the medicine without advice, and tell other clinicians and dentists you take an anticoagulant.

Evidence & guidelines

Non-inferior to warfarin for stroke prevention in atrial fibrillation (ENGAGE AF-TIMI 48) and recommended in UK guidance (NICE NG196).

Reference: ENGAGE-AF TIMI 48 (Giugliano et al. NEJM 2013); NICE NG196 (AF); MHRA SPC Lixiana; NICE NG185 (VTE); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Calculators

Same class

Drugs